Non-chemotherapy drug-induced agranulocytosis

Expert Opinion on Drug Safety

Volumn 6, Issue 3, 2007, Pages 323-335

  Garbe, Edeltraut ^a  

^a LEIBNIZ INSTITUTE FOR PREVENTION RESEARCH AND EPIDEMIOLOGY BIPS   (Germany)

Author keywords

Adverse effectc; Agranulocytosis; Drug induced agranulocytosis; Epidemiology; Haematopoietic cel growth factors

Indexed keywords

ALLOPURINOL; ANALGESIC AGENT; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIMALARIAL AGENT; ANTINEOPLASTIC AGENT; ANTITHYROID AGENT; APRINDINE; CARBAMAZEPINE; CEPHALOSPORIN; CILASTATIN PLUS IMIPENEM; CLOZAPINE; COTRIMOXAZOLE; DIPYRONE; DOXYCYCLINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 3; MACROLIDE; MEROPENEM; PENICILLIN G; PHENOTHIAZINE DERIVATIVE; PROCAINAMIDE; PYRAZOLONE; RITUXIMAB; SALAZOSULFAPYRIDINE; THENALIDINE; TICLOPIDINE; UNINDEXED DRUG; ANTIINFECTIVE AGENT;

AGE DISTRIBUTION; AGRANULOCYTOSIS; ANTIBIOTIC SENSITIVITY; B CELL LYMPHOMA; BLOOD CULTURE; BONE MARROW EXAMINATION; CLINICAL FEATURE; COMORBIDITY; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DNA POLYMORPHISM; DRUG INDUCED DISEASE; DRUG MEGADOSE; FEVER; GENETIC SUSCEPTIBILITY; HEMATOLOGIC DISEASE; HUMAN; INCIDENCE; INFECTIOUS COMPLICATION; MONOTHERAPY; MORTALITY; NEUTROPENIA; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; PATIENT DECISION MAKING; PATIENT MONITORING; PNEUMONIA; PRACTICE GUIDELINE; PROGNOSIS; REVIEW; RISK ASSESSMENT; SEPTICEMIA; SEX DIFFERENCE; SORE THROAT; ACUTE DISEASE; CHEMICALLY INDUCED DISORDER;

ACUTE DISEASE; AGRANULOCYTOSIS; ANTI-BACTERIAL AGENTS; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INCIDENCE; PROGNOSIS;

EID: 34248562058     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.6.3.323     Document Type: Review

References (109)

1. SALAMA A, SCHUTZ B, KIEFEL V, BREITHAUPT H, MUELLER-ECKHARDT C: Immune-mediated agranulocytosis related to drugs and their metabolites: mode of sensitization and heterogeneity of antibodies. Br. J. Haematol. (1989) 72:127-132.
2. KAUFMAN DW, KELLY JP, JURGELON JM et al.: Drugs in the aetiology of agranulocytosis and aplastic anaemia. Eur. J. Haematol. Suppl. (1996) 60:23-30.
3. HEIMPEL H: When should the clinician suspect a drug-induced blood dyscrasia, and how should he proceed? Eur. J. Haematol. Suppl. (1996) 60:11-15.
4. ANDERSOHN F, BRONDER E, KLIMPEL A, GARBE E: Proportion of drug-related serious rare blood dyscrasias: estimates from the Berlin Case-Control Surveillance Study. Am. J. Hematol. (2004) 77:316-318.
5. BOTTIGER LE, WESTERHOLM B: Drug-induced blood dyscrasias in Sweden. Br. Med. J. (1973) 3:339-343.
6. BOTTIGER LE, FURHOFF AK, HOLMBERG L: Drug-induced blood dyscrasias. A ten-year material from the Swedish Adverse Drug Reaction Committee. Acta Med. Scand. (1979) 205:457-461.
7. WIHOLM BE, EMANUELSSON S: Drug-related blood dyscrasias in a Swedish reporting system, 1985 - 1994. Eur. J. Haematol. Suppl. (1996) 60:42-46.
8. RAWSON NS, HARDING SR, MALCOLM E, LUECK L: Hospitalizations for aplastic anemia and agranulocytosis in Saskatchewan: incidence and associations with antecedent prescription drug use. J. Clin. Epidemiol. (1998) 51:1343-1355.
9. STROM BL, CARSON JL, SCHINNAR R, SNYDER ES, SHAW M: Descriptive epidemiology of agranulocytosis. Arch. Intern. Med. (1992) 152:1475-1480.
10. VAN STAA TP, BOULTON F, COOPER C, HAGENBEEK A, INSKIP H, LEUFKENS HG: Neutropenia and agranulocytosis in England and Wales: incidence and risk factors. Am. J. Hematol. (2003) 72:248-254.
11. NO AUTHORS LISTED: Risks of agranulocytosis and aplastic anemia. A first report of their relation to drug use with special reference to analgesics. The International Agranulocyrosis and Aplastic Anemia Study. JAMA (1986) 256:1749-1757.
12. IBANEZ L, VIDAL Y, BALLARIN E, LAPORTE JR: Population-based drug-induced agranulocytosis. Arch. Intern. Med. (2005) 165:869-874.
13. SHAPIRO S, ISSARAGRISIL S, KAUFMAN DW et al.: Agranulocyrosis in Bangkok, Thailand: a predominantly drug-induced disease with an unusually low incidence. Aplastic Anemia Study Group. Am. J. Trop. Med. Hyg. (1999) 60:573- 577.
14. THEOPHILE H, BEGAUD B, MARTIN K, LAPORTE JR, CAPELLA D: Incidence of agranulocytosis in Southwest France. Eur. J. Epidemiol. (2004) 19:563-565.
15. ARNEBORN P PALMBLAD J: Drug-induced neutropenia - a survey for Stockholm 1973 - 1978. Acta Med Scand. (1982) 212:289-292.
16. VAN DER KLAUW MM, GOUDSMIT R, HALIE MR et al.: A population-based case-cohort study of drug-associated agranulocytosis. Arch. Intern. Med. (1999) 159:369-374.
17. KAUFMAN DW, KELLY JP, LEVY M, SHAPIRO S: The drug etiology of agranulocytosis and aplastic anemia. Oxford University Press, New York, USA (1991).
18. ANDERSOHN F, KONZEN C, GARBE E: Non-chemotherapy drug-induced agranulocytosis: a systematic review of case reports. Ann. Intern. Med. (2007) (In Press).
19. DISCOMBE G: Agranulocytosis caused by amidopyrine; an avoidable cause of death. Br. Med. J. (1952) 1:1270-1273.
20. HUGULEY CM Jr: Agranulocytosis induced by dipyrone, a hazardous antipyretic and analgesic. JAMA(1964) 189:938-941.
21. JULIA A, OLONA M, BUENO J et al.: Drug-induced agranulocytosis: prognostic factors in a series of 168 episodes. Br J. Haematol. (1991) 79:366-371.
22. PAITEL JF, STOCKEMER V, DORVAUX V, WITZ F, GUERCI A, LEDERLIN P: Acute drug-induced agranulocytosis. Clinical study apropos of 30 patients and evolution of etiologies over 2 decades. Rev. Med. Interne (1995) 16:495-499.
23. HEDENMALM K, SPIGSET O: Agranulocytosis and other blood dyscrasias associated with dipyrone (metamizole). Eur. J. Clin. Pharmacol. (2002) 58:265-274.
24. SPRIKKELMAN A, DE WOLF JT, VELLENGA E: The application of hematopoietic growth factors in drug-induced agranulocytosis: a review of 70 cases. Leukemia (1994) 8:2031-2036.
25. VIAL T. POFILET C, PHAM E, PAYEN C, EVRELJX JC: Acute drug-induced agranulocytosis: experience of the Regional Center of Pharmacovigilance of Lyon over 7 years. Therapie(1996) 51:508-515.
26. ANDRES E, MALOISEL F, KURTZ JE et al.: Modern management of non-chemotherapy drug-induced agranulocytosis: a monocentric cohort study of 90 cases and review of the literature. Eur. J. Intern. Med. (2002) 13:324-328.
27. CAREY PJ: Drug-induced myelosuppression: diagnosis and management. Drug Saf (2003) 26:691-706.
28. BHATT V, SALEEM A: Review: drug-induced neutropenia-pathophysiology, clinical features, and management. Ann. Clin. Lab. Sci. (2004) 34:131-137.
29. VIAL T. GALLANT C, CHOQUET-KASTYLEVSKY G, DESCOTES J: Treatment of drug-induced agranulocytosis with haematopoietic growth factors. Biodrugs (1999) 11:185-200.
30. RUVIDIC R, JELIC S: Haematological aspects of drug-induccd agranulocytosis. Scand J. Haematol. (1972) 9:18-27.
31. YOUNG NS: Agranulocytosis. JAMA (1994) 271:935-938.
32. ANDRES E, MALOISEL F: Idiosyncratic drug-induced agranulocytosis. Rev. Med. Interne. (2006) 27:209-214.
33. HEIMPEL H: Drug-induced agranulocytosis. Med. Toxicol. Adverse Drug Exp. (1988) 3:449-462.
34. ANDRES E, ZIMMER J, AFFENBERGER S, FEDERICI L, ALT M, MALOISEL F: Idiosyncratic drug-induced agranulocytosis: update of an old disorder. Eur. J. Intern. Med. (2006) 17:529-535.
35. MALOISEL F, ANDRES E, KALTENBACH G, NOEL E, MARTIN-HUNYADI C, DUFOUR P: Prognostic factors of hematological recovery in life-threatening nonchemotherapy drug-induced agranulocytosis. A study of 91 patients from a single center. Presse Med. (2004) 33:1164-1168.
36. SMITH TJ, KHATCHERESSIAN J, LYMAN G H et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J. Clin. Oncol. (2006) 24:3187-3205.
37. NO AUTHORS LISTED: Risk of agranulocytosis and aplastic anaemia in relation to use of antithyroid drugs. International Agranulocytosis and Aplastic Anaemia Study. Br. Med. J. (1988) 297:262-265.
38. NO AUTHORS LISTED: Anti-infective drug use in relation to the risk of agranulocytosis and aplastic anemia. A report from the International Agranulocytosis and Aplastic Anemia Study. Arch. Intern. Med. (1989) 149:1036-1040.
39. KELLY JP, KAUFMAN DW, SHAPIRO S: Risks of agranulocytosis and aplastic anemia in relation to the use of cardiovascular drugs: tThe International Agranulocytosis and Aplastic Anemia Study. Clin. Pharmacol. Ther. (1991) 49:330-341.
40. STROM B1, CARSON JL, SCHINNAR R, SNYDER ES, SHAW M, LUNDIN FE Jr: Nonsteroidal anti-inflammatory drugs and neutropenia. Arch. Intern. Med. (1993) 153:2119-2124.
41. TOHEN M, CASTILLO J, BALDESSARINI RJ, ZARATE C, KANDO JC: Blood dyscrasias with carbamazepine and valproate: a pharmacoepidemiological study of 2,228 patients at risk. Am. J. Psychiatry (1995) 152:413-418.
42. BLACKBURN SC, OLLART AD, GARCIA RODRIGUEZ LA, PEREZ GS: Antiepileptics and blood dyscrasias: a cohort study. Pharmacotherapy (1998) 18:1277-1283.
43. HUERTA C, GARCIA RODRIGUEZ LA: Risk of clinical blood dyscrasia in a cohort of antibiotic users. Pharmacotherapy (2002) 22:630-636.
44. DEL REY MJ, LOPEZ CORTES LF, GOMEZ MATEOS JM, LOZANO DL: Agranulocytosis caused by ticlopidine. Neurologia (1992) 7:121-122.
45. GUERCIOLINI R, GIORDANO G, AVERSA F, DEL FAVERO A. Anaemia and agranulocyrosis associated with ticlopidine therapy. Acta Haematol. (1985) 73:232-234.
46. JOHANNING RJ, TSCHIDA SJ: Comment: Pscudomonas bacteremia secondary to ticlopidine-induced agran ulocytosis. Ann. Pharmacother. (1996) 30:1201.
47. LAGIER C, VIAL T, RABILLOUD M, EVREUX JC: Agranulocytosis during a treatment with nitrendipine and ticlopidine. Therapie (1991) 46:169-170.
48. LEGARRA G, BELTRAN DE HEREDIA JM, OLABARRIA I, MENOYO, MV, VILLARREAL JJ: Agranulocytosis caused by ticlopidine. Sangre (Barc.) (1994) 39:229-230.
49. MARINELLA MA: Agranulocytosis associated with ticlopidine: a possible benefit with filgastim. Ann. Clin. Lab. Sci. (1997) 27:418-421.
50. MARMONT AM, LOTTI G, NATI S, MARTINENGO M, MORGANO A: Agranulocytosis caused by ticlopidine. Recenti Prog. Med. (1985) 76:245-248.
51. ONO K, KUROHARA K, YOSHIHARA M, SHIMAMOTO Y, YAMAGUCHI M: Agranulocytosis caused by ticlopidine and its mechanism. Am. J. Hematol. (1991) 37:239-242.
52. RIMBROT S, KUNDZINSH E, LEVY Y: Invasive aspergillosis in a patient with ticlopidine-induced agranulocytosis. Arch. Intern. Med. (2000) 160:3498-3499.
53. SAINT-MARC GIRARDIN MF, CORDONNIER C: Cholestatic icterus and agranulocytosis due to ticlopidine. Gastroenterol. Clin. Biol. (1982) 6:716-717.
54. SARI R, SEVINC A, BUYUKBERBER S: Ticlopidine-induced severe agranulocytosis after the placement of coronary artery stent - a case report. Angiology (2000) 51:591-593.
55. SCHNEIDER AW, FECHLER L, GILFRICH HJ: Ticlopidine-induced pancytopenia: therapy of agranulocytosis with granulocyte colony stimulating factor. Med. Klin. (Munich) (1996) 91:417-419.
56. THOMSON LE, STEWART JT: Ticlopidine induced agranulocytosis managed with granulocyte colony stimulating factor. NZ Med. J. (1998) 111:81-82.
57. ALVIR JM, LIEBERMAN JA, SAFFERMAN AZ, SCHWIMMER JL, SCHAAF JA: Clozapine-induced agranulocytosis. Incidence and risk factors - in the United States. N. Engl. J. Med. (1993) 329:162-167.
58. COPOLOV DL, BELL WR, BENSON WJ, KEKS NA, STRAZZERI DC, JOHNSON GF: Clozapine treatment in Australia: a review of haematological monitoring. Med. J. Aust. (1998) 168:495-497.
59. MEYER O, GAEDICKE G, SALAMA A: Demonstration of drug-dependent antibodies in two patients with neutrophenia and successful treatment with granulocyte-colony-stimulating factor. Transfusion (1999) 39:527-530.
60. CAIROLI R, GRILLO G, TEDESCHI A, D'AVANZO G, MARENCO P, MORRA E: High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation. Haematologica (2004) 89:361-363.
61. CHAIWATANATORN K, LEE N, GRIGG A, FILSHIE R, FIRKIN F: Delayed-onset neutropenia associated with rituximab therapy. Br. J. Haematol. (2003) 121:913-918.
62. HOFER S, VIOLLIER R, LUDWIG C: Delayed-onset and long-lasting severe neutropenia due to rituximab. Swiss. Med. Wkly. (2004) 134:79-80.
63. LEMIEUX B, TARTAS S, TRAULLE C et al.: Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant. (2004) 33:921-923.
64. MITSUHATA N, FUJITA R, ITO S, MANNAMI M, KEIMEI K: Delayed-onset neutropenia in a patient receiving rituximab as treatment for refractory kidney transplantation. Transplantation (2005) 80:1355.
65. VOOG E, MORSCHHAUSER F, SOLAL-CELIGNY P: Neutropenia in patients treated with rituximab. N. Engl. J. Med. (2003) 348:2691-2694.
66. BENICHOU C, SOLAL CP: Standardization of definitions and criteria for causality assessment of adverse drug reactions. Drug-induced blood cytopenias: report of an international consensus meeting. Nouv. Rev. Fr. Hematol. (1991) 33:257-262.
67. NITTA E, IZUTSU K, SATO T et al.: A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study. Ann. Oncol. (2007) 18:364-369.
68. STRONCEK DF: Drug-induced immune neutropenia. Transfus. Med. Rev. (1993) 7:268-274.
69. WEITZMAN SA, STOSSEL TP: Drug-induced immunological neutropenia. Lancet (1978) 1:1068-1072.
70. HASEGAWA T, BERGH OJ, TERASAKI PI, GRAW RG: Occurrence of granulocyte cytotoxins and agglutinins. Transfusion (1975) 15:226-230.
71. WALL JR, FANG SL, KUROKI T, ING BAR SH, BRAVERMAN LE: In vitro immunoreactivity to propylthiouracil, methimazole, and carbimazole in patients with Graves' disease: a possible cause of antithyroid drug-induced agranulocytosis. J. Clin. Endocrinol. Metab. (1984) 58:868-872.
72. PISCIOTTA V: Drug-induced agranulocytosis. Drugs (1978) 15:132-143.
73. WILLIAMS DP, PIRMOHAMED M, NAISBITT DJ, MAGGS JL, PARK BK: Neutrophil cytotoxicity of the chemically reactive merabolite(s) of clozapine: possible role in agranulocytosis. J. Pharmacol. Exp. Ther. (1997) 283:1375-1382.
74. BOOGAERTS MA, PETERS M, PEERSMAN C, KESTELOOT H, VERWILGHEN RL: Mechanism of aprindine induced agranulocytosis: direct toxicity on CFU-C and CFU-GEMM. Scand. J. Haematol. (1984) 32:175-178.
75. WILLIAMS DP, PIRMOHAMED M, NAISBITT DJ, UETRECHT JP, PARK BK: Induction of metabolism-dependent and -independent neutrophil apoptosis by clozapine. Mol. Pharmacol. (2000) 58:207-216.
76. GUZELCAN Y, SCHOLTE WF: Clozapine-induced agranulocytosis: genetic risk factors and an immunologic explanatory model. Tijdschr. Pychiatr. (2006) 48:295-302.
77. PEREIRA A, DEAN B: Clozapine bioactivation induces dose-dependent, drug-specific toxicity of human bone marrow stromal cells: a potential in vitro system for the study of agranulocytosis. Biochem. Pharmacol. (2006) 72(6):783-793.
78. AMAR A, SEGMAN RH, SHTRUSSBERG S et al.: An association between clozapine-induced agranulocytosis in schizophrenics and HLA-DQB1*0201. Int. J. Neuropsychopharmcol. (1998) 1:41-44.
79. DETTLING M, CASCORBI I, ROOTS I, MUELLER-OERLINGHAUSEN B: Genetic determinants of clozapine-induced agranulocytosis: recent results of HLA subtyping in a non-jewish caucasian sample. Arch. Gen. Psychiatry (2001) 58:93-94.
80. MARCHINI M, SCORZA R, ANTONIOLI R et al.: HLA-A2 and B35 are strong predictors of responsiveness to clozapine: preliminary data in Italian schizophrenia patients. Schizophr. Res. (2001) 48:363-365.
81. VALEVSKI A, KLEIN T, GAZIT E et al.: HLA-B38 and clozapine-induced agranulocytosis in Israeli Jewish schizophrenic patients. Eur. J. Immunogenet. (1998) 25:11-13.
82. CLAAS FH, ABBOTT PA, WITVLIET MD, D'AMARO J, BARNES PM, KRUPP P: No direct clinical relevance of the human leucocyte antigen (HLA) system in clozapine-induced agranulocytosis. Drug Saf. (1992) 7(Suppl. 1):3-6.
83. HUGHES WT, ARMSTRONG D, BODEY G P et al.: 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin. Infect. Dis. (2002) 34:730-751.
84. NO AUTHORS LISTED: Empiric antifungal therapy in febrile granulocytopenic patients. EORTC International Antimicrobial Therapy Cooperative Group. Am. J. Med. (1989) 86:668-672.
85. PALMBLAD J, JONSON B, KANERUD L: Treatment of drug-induced agranulocytosis with recombinant GM-CSF. J. Intern. Med. (1990) 228:537-539.
86. TEITELBAUM AH, BELL AJ, BROVIN SL: Filgrastim (r-metHuG-CSF) reversal of drug-induced agranulocytosis. Am. J. Med. (1993) 95:245-246.
87. MANI S, BARRY M, CONCATO J: Granulocyte-colony stimulating factor therapy in drug-induced agranulocytosis. Arch. Intern. Med. (1993) 153:2500-2501.
88. HUNT KA, RESNICK MP: Clomipramine-induced agranulocytosis and its treatment with G-CSF. Am. J. Psychiatry (1993) 150:522-523.
89. HUNAULT M, DOMBRET H, GARDIN C et al.: Hematopoietic growth factors in drug-induced agranulocytosis. Leukemia (1995) 9:1286-1287.
90. KENDRA JR, RUGMAN FP, FLAHERTY TA et al.: First use of G-CSF in chlorpromazine-induced agranulocytosis: a report of two cases. Postgrad. Med. J. (1993) 69:885-887.
91. MEANS RT Jr, SANDIDGE DR, RANKIN KM, ROBICHAUX MR Jr: Treatment of phenothiazine-induced agranulocytosis with recombinant granulocyte colony-stimulating factor. Am. J. Hematol. (1992) 41:296.
92. WEISS M, GROSS-WEEGE W, WERNET P: Rapid neutrophil recovery from acquired agranulocytosis by recombinant human granulocyte-macrophage colony-stimulating factor in an intensive care patient. Crit. Care Med. (1992) 20:1490-1491.
93. GROSS-WEEGE W, WEISS M, WERNET P. VARNEY M, BECKER H: Instant therapy of acquired agranulocytosis and sepsis by recombinant granulocyte-macrophagecolony-stimulating factor in a polytrauma patient. Clin. Investig. (1993) 71:791-794.
94. CHIA HM, KALRA L, LAKHANI AK, SAMARATUNGA IR: Filgrastim for low-dose, capropril-induced agranulocytosis. Lancet (1993) 342:304.
95. WALLACH FR, ZIRN J, MURRAY HW, TEPLER J, LUGER NM: Use of granulocyte-macrophage colony stimulating factor for treatment of drug-induced agranulocytosis. Rev. Infect. Dis. (1991) 13:523.
96. MARTINO R, MARTINEZ E, SUREDA A, MONTAGUD M: A favorable response to the granulocyte colony-stimulating factor in a patient with agranulocytosis associated with the use of intravenous immunoglobulin. Med. Clin. (Barr.) (1993) 100:358-359.
97. NAND S, BAYER R, PRINZ RA, FELTEN W, GODWIN JE: Granulocyte-macrophage colony stimulating factor for the treatment of drug induced agranulocytosis. Am. J. Hematol. (1991) 37:267-269.
98. CAPPELLARI G, GAIO A, CAVALLARO A et al.: Use of colony stimulating factors for the treatment of drug-induced agranutocytosis. Br. J. Haematol. (1993) 84:183-184.
99. GALES BJ, GALES MA: Granulocyte-colony stimulating Factor for sulfasalazine-induced agranulocytosis. Ann. Pharmacother. (1993) 27:1052-1054.
100. KUIPERS EJ, VELLENGA E, DE WOLF JT, HAZENBERG BP: Sulfasalazine induced agranulocytosis treated with granulocyte-macrophage colony stimulating factor. J. Rheumatol. (1992) 19:621-622.
101. RODDIE P, DORRANCE H, COOK MK, RAINEY JB: Treatment of sulphasalazine-induced agmulocytosis with granulocyte macrophage-colony stimulating factor. Aliment. Pharmacol. Ther. (1995) 9:711-712.
102. GORA-TYBOR J, KRYKOWSKI E, ROBAK T. Treatment of drug-induced agranulocytosis with colony stimulating factors (G-CSF or GM-CSF). Arch. Immunol. Ther. Exp. (Warsz,) (1996) 44:255-258.
103. ANDRES E, KURTZ JE, PERRIN AE, DUFOUR P, SCHLIENGERJL, MALOISEL F: Haematopoietic growth factor in antithyroid-drug-induced agranulocytosis. QJM (2001) 94:423-428.
104. ANDRES E, MALOISEL F: Granulocyte-colony stimulating factor (G-CSF) therapy in antithyroid drug-induced agranulocytosis. Endocr. J. (2005) 52:383.
105. TAJIRI J, NOGUCHI S: Antithyroid drug-induced agranulocytosis: how has granulocyte colony-stimulating factor changed therapy? Thyroid (2005) 15:292-297.
106. BEAUCHESNE MF, SHALANSKY SJ: Nonchemotherapy drug-induced agranulocytosis: a review of 118 patients treated with colony-stimulating factors. Pharmacotherapy (1999) 19:299-305.
107. ANDRES E, KURTZ JE, MARTIN-HUNYADI C et al.: Nonchemothcrapy drug-induced agranutocytosis in elderly patients: the effects of granulocyte colony-stimulating lactor. Am. J. Med. (2002) 112:460-464.
108. ANDRES E, MALOISEL F, RUELLAN A: Use of colony-stimulating factors for the treatment of antithyroid drug-induced agranulocytosis: a retrospective study in twelve patients. Thyroid (2000) 10:103.
109. FUKATA S, KUMA K, SUGAWARA M: Granulocyte colony-stimulating factor (G-CSF) does not improve recovery from antithyroid drug-induced agranulocyrosis: a prospective study. Thyroid (1999) 9:29-31.